Needham & Company LLC restated their buy rating on shares of Biohaven Pharm (NYSE:BHVN) in a report published on Wednesday. They currently have a $36.00 price target on the stock.

“Biohaven reported 3Q17 financial results and we spoke w/ mgmt for an update. Rimegepant Phase 3 trials in Acute Migraine are nearing completion of enrollment and mgmt reiterated guidance for top-line results in 1Q18. We expect a positive outcome based on strength of Phase 2b data. Biohaven recently initiated a registration bioequivalence trial of BHV-0223 in Amyotrophic Lateral Sclerosis (ALS) and we believe results will be available in early 2018. We expect company to submit 505(b)(2) application (oral riluzole disintegrating tablet) by mid-2017. BHV5000 IND submission is on track, but BH3500 has been pushed into 2018 because of technical regulatory matters tied to manufacturing. Reiterate BUY, w/ expectations for upside around rimegepant Phase 3 outcome.”,” Needham & Company LLC’s analyst commented.

Other research analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Biohaven Pharm from a buy rating to a strong-buy rating in a report on Thursday, September 28th. William Blair reiterated an outperform rating on shares of Biohaven Pharm in a report on Tuesday, October 3rd. Piper Jaffray Companies reiterated a buy rating and set a $54.00 price target on shares of Biohaven Pharm in a report on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Biohaven Pharm from a sell rating to a hold rating in a report on Tuesday, August 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $40.80.

Biohaven Pharm (NYSE BHVN) traded up $0.22 during midday trading on Wednesday, reaching $25.61. 169,946 shares of the company’s stock traded hands, compared to its average volume of 225,179. Biohaven Pharm has a 12 month low of $17.00 and a 12 month high of $39.51.

TRADEMARK VIOLATION WARNING: “Biohaven Pharm (BHVN) Earns “Buy” Rating from Needham & Company LLC” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/biohaven-pharm-bhvn-earns-buy-rating-from-needham-company-llc.html.

In other news, CFO James Engelhart sold 30,538 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $26.58, for a total value of $811,700.04. Following the completion of the transaction, the chief financial officer now owns 25,176 shares in the company, valued at approximately $669,178.08. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Robert Berman sold 160,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total transaction of $4,121,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 402,961 shares of company stock valued at $11,098,152.

Institutional investors have recently modified their holdings of the company. Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharm in the 3rd quarter valued at $374,000. Strs Ohio acquired a new position in shares of Biohaven Pharm in the 3rd quarter valued at $680,000. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Biohaven Pharm in the 3rd quarter valued at $2,790,000. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Biohaven Pharm in the 3rd quarter valued at $7,483,000. Finally, Emerald Advisers Inc. PA acquired a new position in shares of Biohaven Pharm in the 3rd quarter valued at $9,096,000. Institutional investors and hedge funds own 44.03% of the company’s stock.

Biohaven Pharm Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharm (NYSE:BHVN)

Receive News & Stock Ratings for Biohaven Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharm and related stocks with our FREE daily email newsletter.